ARCHIVES

Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

Advocacy Groups Consider Pros And Cons Of Forming Co-Pay Foundations.

April 28, 2006

Cediranib/Olaparib Combination Nearly Doubles PFS in Phase II

September 26, 2014

“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says

September 25, 1998

New Reagan Budget Or FY 1982 gives NCI $1.026 Billion

March 6, 1981

FDA Describes Meeting With NCI In “Limited” Memo

May 7, 1976

In Brief: Names Submitted For NIH Deputy Director; Gottesman Leads Genome Project Temporarily

May 8, 1992